Cogent Biosciences Inc

Research Cogent Biosciences Inc (COGT) on Bullrun: market cap USD 6.62B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCOGT
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 6.62B
• Financial periodFY2025
• Net income-USD 328.94M
• Free cash flow-USD 266.00M

Valuation Snapshot

latest market cap is USD 6.62B.

About Cogent Biosciences Inc

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.

Frequently asked questions

What is Cogent Biosciences Inc's market cap?

Cogent Biosciences Inc's market capitalization is USD 6.62B.

What does Cogent Biosciences Inc do?

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases.